23.36

2.77% 0.63

Pre-market: 24.45 1.09 +4.67%

Nektar Therapeutics (NKTR)

Overview News Price History Option Chain Financials Discussions Forecast Stock Split

Nektar Therapeutics stock is traded at $23.36, with a volume of 1.26M. It is up +2.77% in the last 24 hours and up +165.76% over the past month. Nektar Therapeutics is a clinical-stage, research-based drug discovery biopharmaceutical company focused on discovering and developing medicines in the field of immunotherapy. The company is focused on discovering and developing medicines in the field of immunotherapy. Its pipeline products are REZPEG (NKTR-358), REZPEG (NKTR-358), REZPEG (NKTR-358), NKTR-422, NKTR-0165, NKTR-255, and Others.

Previous Close:

$22.73

Open:

$23.25

24h Volume:

1.26M

Relative Volume:

0.63

Market Cap:

$140.82M

Revenue:

$90.12M

Net Income/Loss:

$-276.06M

P/E Ratio:

-16.00

EPS:

-1.46

Net Cash Flow:

$-193.47M

1W Performance:

-8.50%

1M Performance:

+165.76%

6M Performance:

+1,949%

1Y Performance:

+1,799%

1-Day Range:

$22.61

$23.97

1-Week Range:

$21.87

$26.43

52-Week Range:

$0.432

$37.38

Nektar Therapeutics Stock (NKTR) Company Profile

Name

Nektar Therapeutics

Sector

Healthcare (1163)

Industry

Biotechnology (652)

Phone

(415) 482-5300

Address

455 MISSION BAY BOULEVARD SOUTH, SAN FRANCISCO, CA

Employee

Twitter

@nektarnews

Next Earnings Date

2025-03-12

Latest SEC Filings

NKTR's Discussions on Twitter

Compare NKTR with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
NKTR Nektar Therapeutics	23.36	140.82M	90.12M	-276.06M	-193.47M	-1.46
VRTX Vertex Pharmaceuticals Inc	478.96	115.95B	11.10B	-988.90M	-1.26B	-3.92
REGN Regeneron Pharmaceuticals Inc	552.58	56.52B	14.09B	4.50B	2.96B	39.28
ALNY Alnylam Pharmaceuticals Inc	320.87	39.44B	2.35B	-269.70M	-75.39M	-2.09
ARGX Argen X Se Adr	555.19	35.14B	2.58B	1.06B	-1.28B	16.33
ONC Beone Medicines Ltd Adr	255.69	28.51B	3.81B	-644.79M	-669.77M	-6.24

Nektar Therapeutics Stock (NKTR) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Apr-11-25	Upgrade	Jefferies	Hold → Buy
Mar-14-25	Upgrade	Oppenheimer	Perform → Outperform
Jan-08-25	Initiated	B. Riley Securities	Buy
Dec-10-24	Initiated	H.C. Wainwright	Buy
Nov-04-24	Initiated	Piper Sandler	Overweight
Sep-30-24	Resumed	BTIG Research	Buy
Jun-28-24	Initiated	Rodman & Renshaw	Buy
Nov-20-23	Resumed	JP Morgan	Underweight
Nov-09-23	Upgrade	TD Cowen	Market Perform → Outperform
May-10-23	Upgrade	Jefferies	Underperform → Hold
Feb-24-23	Downgrade	Jefferies	Hold → Underperform
Aug-08-22	Downgrade	JP Morgan	Neutral → Underweight
May-31-22	Resumed	Jefferies	Hold
Apr-18-22	Downgrade	Goldman	Neutral → Sell
Mar-15-22	Downgrade	Cowen	Outperform → Market Perform
Mar-15-22	Downgrade	Mizuho	Buy → Neutral
Mar-14-22	Downgrade	BTIG Research	Buy → Neutral
Mar-14-22	Downgrade	BofA Securities	Neutral → Underperform
Mar-14-22	Downgrade	Stifel	Buy → Hold
Mar-14-22	Downgrade	William Blair	Outperform → Mkt Perform
Mar-09-22	Upgrade	Oppenheimer	Perform → Outperform
Nov-08-21	Upgrade	The Benchmark Company	Hold → Buy
Sep-10-21	Initiated	BofA Securities	Neutral
Jun-28-21	Upgrade	Stifel	Hold → Buy
May-18-21	Resumed	Goldman	Neutral
Feb-22-21	Downgrade	The Benchmark Company	Buy → Hold
Jan-06-21	Initiated	Stifel	Hold
Sep-14-20	Initiated	JP Morgan	Neutral
Jun-10-20	Downgrade	CFRA	Hold → Sell
May-12-20	Reiterated	H.C. Wainwright	Neutral
Apr-22-20	Initiated	The Benchmark Company	Buy
Mar-30-20	Upgrade	Goldman	Sell → Neutral
Mar-04-20	Initiated	Barclays	Overweight
Feb-03-20	Upgrade	Mizuho	Neutral → Buy
Oct-24-19	Initiated	Oppenheimer	Perform
Oct-08-19	Downgrade	Goldman	Buy → Sell
Aug-09-19	Downgrade	JP Morgan	Overweight → Neutral
Aug-09-19	Downgrade	Jefferies	Buy → Hold
Aug-09-19	Downgrade	Mizuho	Buy → Neutral
Mar-15-19	Initiated	SVB Leerink	Mkt Perform
Dec-13-18	Initiated	Goldman	Buy
Jun-11-18	Downgrade	H.C. Wainwright	Buy → Neutral
Jun-04-18	Reiterated	H.C. Wainwright	Buy
Apr-20-18	Initiated	Seaport Global Securities	Buy
Apr-13-18	Resumed	Piper Jaffray	Overweight
Apr-06-18	Reiterated	Mizuho	Buy
Apr-02-18	Resumed	H.C. Wainwright	Buy

View All

Nektar Therapeutics Stock (NKTR) Latest News

Jun 16, 2025

Alopecia Areata Market Expected to Experience Major Growth by 2034, According to DelveInsight | Pfizer, Suzhou Zelgen Biopharma, Eli Lilly/ Incyte, Throne Biotech, Legacy Healthcare - Barchart.com

Jun 16, 2025

Jun 11, 2025

Nektar Therapeutics: 2 Data Readouts For REZPEG 2025 Could Establish Further POC (NKTR) - Seeking Alpha

Jun 11, 2025

Nektar Therapeutics (NASDAQ:NKTR) Shares Fly 29% But Investors Aren't Buying For Growth - simplywall.st

Jun 11, 2025

Jun 08, 2025

Nektar therapeutics outlines REZOLVE-AD phase 2b data and financial position for Q2 2025 - MSN

Jun 08, 2025

Jun 06, 2025

Millennium Management LLC Sells 536,773 Shares of Nektar Therapeutics (NASDAQ:NKTR) - Defense World

May 30, 2025

May 29, 2025

Natural Killer (NK)-Cell Lymphoma Pipeline Appears Robust With 100+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight - The Globe and Mail

May 29, 2025

D. E. Shaw & Co. Inc. Grows Stake in Nektar Therapeutics (NASDAQ:NKTR) - Defense World

May 29, 2025

May 28, 2025

Metastatic renal cell carcinoma Pipeline 2025: Groundbreaking - openPR.com

May 28, 2025

BNP Paribas Financial Markets Acquires 73,847 Shares of Nektar Therapeutics (NASDAQ:NKTR) - Defense World

May 28, 2025

Nektar Therapeutics Elects New Board, Approves Key Proposals - TipRanks

May 28, 2025

May 26, 2025

Natural Killer (NK)-Cell Lymphoma Market to Expand - openPR.com

May 26, 2025

Natural Killer (NK)-Cell Lymphoma Market to Expand Significantly by 2032, States DelveInsight Report | Innate Pharma, Nektar Therapeutics, ImmunityBio, CytoVac, Celularity - The Globe and Mail

May 26, 2025

May 23, 2025

Have Insiders Sold Nektar Therapeutics Shares Recently? - simplywall.st

May 23, 2025

May 22, 2025

Nektar Therapeutics (NASDAQ:NKTR) Receives $4.50 Average Target Price from Analysts - Defense World

May 22, 2025

May 20, 2025

Moderate to Severe Atopic Dermatitis Clinical Trial Pipeline Insights Featuring 45+ Companies | DelveInsight - GlobeNewswire

May 20, 2025

Nektar Therapeutics To Present At H.C. Wainwright BioConnect Conference; Webcast At 1:30 PM ET - Nasdaq

May 20, 2025

May 16, 2025

Nektar Therapeutics (NASDAQ:NKTR) Rating Lowered to “Sell” at StockNews.com - Defense World

May 16, 2025

What is William Blair’s Estimate for NKTR Q2 Earnings? - Defense World

May 16, 2025

May 15, 2025

Nektar Therapeutics (NASDAQ:NKTR) Analysts Are More Bearish Than They Used To Be - simplywall.st

May 15, 2025

Voya Investment Management LLC Acquires 121,187 Shares of Nektar Therapeutics (NASDAQ:NKTR) - Defense World

May 15, 2025

Q2 EPS Estimate for Nektar Therapeutics Decreased by Analyst - Defense World

May 15, 2025

May 14, 2025

GSK’s liver asset play grows group of $1B upfront deals - biocentury.com

May 14, 2025

Nektar Therapeutics (NASDAQ:NKTR) Analysts Are Cutting Their Estimates: Here's What You Need To Know - Yahoo Finance

May 14, 2025

May 13, 2025

Nektar Therapeutics to Participate in the H.C. Wainwright 3rd Annual BioConnect Investor Conference - Kilgore News Herald

May 13, 2025

Nektar Therapeutics to Participate in the H.C. Wainwright 3rd An - GuruFocus

May 13, 2025

Nektar Q1 Loss Wider Than Expected, Revenues Fall Y/Y, Stock Down - MSN

May 13, 2025

Time To Worry? Analysts Are Downgrading Their Nektar Therapeutics (NASDAQ:NKTR) Outlook - Yahoo Finance

May 13, 2025